アルゴリズム社とは

アルゴリズム社の概要

DynamicImage

出典:http://www.algorithm- lb.com/Health_Awareness/English/ Navigation/Hyperuricemia_and_Gout

Algorithm社の概要

Algorithm社は、従業員数445名、連結売上高1.4億ドルを超える製薬企業グループの構成企業です。

会 社 名 : Algorithm SAL
設 立 : 1989年
社 長 : Mr. Selim J. Ghorayeb
所 在 地 : Zouk Mosbeh, sea road, Algorithm bldg, Beirut, Lebanon
従業員数 : 242名(2009年12月現在)
売 上 高 : 1,700万ドル(2009年)
事業内容 : 医薬品の製造・開発・販売

 

Algorithm社は、中枢神経系疾患、内分泌・代謝性疾患、循環器系疾患、癌・血液
系疾患、皮膚疾患、泌尿器系疾患等を注力分野とするレバノンの製薬企業です。また
同社は数多くの日欧米の製薬企業と提携し、積極的な製品拡充を図っています。2008
年時点での医薬品売上は約 130億円であり、65の製品を販売しております。

 

同社のHP-Profileにて

アルゴリズムは、評判の良い国際的な企業からのライセンスの下や、同社の製品開発チームによって開発された高品質な製品を提供に専念しています。 ポートフォリオは、革新的な製品だけでなく、差別化ジェネリックで構成され、以下の治療分野(心臓病学、内分泌学、神経学、婦人科や泌尿器科)を中心に、自社製品とBiologix FZCO、アルゴリズムとの提携を通じ、中東と北アフリカで積極的に貢献しています。

との記述もあります。

アルゴリズム社の歴史

アルゴリズム社の歴史

1961
  • Plant established in Lebanon as “CHARLES. E. FROSST & CO. (M.E.) S.A.L”. It was initially built in 1962 and later expanded in 1974. It has operated as a subsidiary of MERCK & CO. INC. (MSD) until December 1989
1989
  • Ownership transferred to a group of Lebanese nationals, shareholders of Droguerie de L’Union – distributors of MSD in Lebanon. The company name was changed to ALGORITHM SAL.
    All manufactured products were still under license from MSD
1997
  • Agreement with Recordati to manufacture and promote its products in the Middle East, namely Lercadip, Lomexin and Urispas
  • Strategic alliance with Biogen to market Avonex (interferon beta 1-a) in the MENA region. Avonex being a biotech product indicated for multiple sclerosis
1998
  • Launch of Lercadip (lercanidipine); the first 3rd generation lipophilic Calcium Antagonist Dihydropiridine indicated for Hypertension.
  • Launch of the first one shot gynecological antifungal treatment, Lomexin (fenticonazole).
  • Launch of Urispas (flavoxate) creating the untapped market of urge incontinence
  • Launch of the first generic: Captace (captopril) enhancing the presence of Algorithm in the cardiovascular field
1999
  • Partnership with Eli Lilly focusing on the Lebanese market
2003
  • Regional service agreement with Biologix FZCo (based in Dubai, UAE) for the promotion of biotech products
2004
  • Expansion of the regional biotech business to promote products of Astellas and Cephalon
2007
  • Further expansion with new regional agreements with Shire, Tercica and Celgene
2008
  • Global acquisition of Aggrastat (tirofiban) by Iroko Cardio LLC from Merck & Co. Marketing in the Middle East granted to Algorithm.
  • Expansion of the partnership with Lilly to include promotion of products in the Gulf: Glustin, Prozac and Evista
2009
  • Regional agreement with Ipsen to promote its portfolio in most markets of the area
2010
  • Launch of Silosin (silodosin, under license from Recordati & Kissei) indicated for BPH. The launch in Lebanon was the 3rd one worldwide after the launches in Japan and USA
  • Launch of Zanipress, the only antihypertensive with a fixed combination of a Dihydropiridine Calcium Antagonist (lercanidipine) and an ACE Inhibitor (enalapril), also under license form Recordati
2011
  • Launch of Livazo (pitavastatin) under-license from Kowa. Livazo is the only potent statin uniquely combining effective control on LDL-C & TG, unique long-term incremental HDL-C increase and superior safety profile
  • Expansion of the partnership with MSD in Lebanon to include the promotion of Cozaar, Hyzaar, Fortzaar, Maxalt, Proscar & Remeron.

 

アルゴリズム社との協力会社

アルゴリズム社パートナー

Algorithm has build throughout the years strong partnerships with many international pharmaceutical and biotech companies. These partnerships consist of manufacturing and/or marketing pharmaceutical and biotech products in different areas in Middle East and North Africa

 

TOPへ戻る